BioCentury
ARTICLE | Clinical News

Pfizer's Sutent improves survival without surgery in RCC patients

June 8, 2018 3:27 PM UTC

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma (RCC) could avoid nephrectomy without compromising survival. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

CARMENA enrolled 450 patients with synchronous metastatic RCC to receive Sutent alone or Sutent 4-6 weeks after surgery. The open-label, French, non-inferiority trial was sponsored by Assistance Publique - Hôpitaux de Paris and was conducted in collaboration with Pfizer...